2026 4th Advanced Regenerative Medicine Clinical Research Activation Support Project New Task Announcement
- Eligible
- Research and development institutions (regenerative medicine institutions) approved by the Committee on Safety and…
- Deadline
- 마감일 원문 확인
This announcement supports new tasks for activating advanced regenerative medicine clinical research. The General type supports clinical research conducted by regenerative medicine institutions, while the Deepening type supports follow-up research to verify reproducibility of prior studies. Eligible applicants are institutions that have received suitability approval from the relevant committees in accordance with applicable laws.
3-second summary
- Lead Agency: Korea Institute of Science and Technology Evaluation and Planning (KISTEP)
- Target Audience: Entities subject to Articles 12 and 13 of the Act on Safety and Support of Advanced Regenerative Medicine and Biopharmaceuticals
- Eligibility: Institutions conducting clinical research approved by the review committee (divided into General and Deepening types)
Eligibility checklist
- Institutions conducting clinical research that has received suitability approval from the committee under Articles 12 and 13 of the Act on Safety and Support of Advanced Regenerative Medicine and Biopharmaceuticals
- [General Type] R&D institutions (regenerative medicine institutions) intending to conduct advanced regenerative medicine clinical research
- [Deepening Type] R&D institutions (regenerative medicine institutions) intending to verify reproducibility of prior advanced regenerative medicine clinical research
Recommended for
- Recommended for representatives of regenerative medicine institutions currently conducting or planning advanced regenerative medicine clinical research.
- Recommended for representatives of R&D institutions preparing follow-up research to verify the reproducibility of prior clinical studies.
Frequently asked questions
Who is eligible to apply?
This program is for Research and development institutions (regenerative medicine institutions) approved by the Committee on Safety and…. Details: Institutions conducting clinical research that has received suitability approval from the committee under Articles 12 and 13 of the Act on Safety and Support of Advanced Regenerative Medicine and Biopharmaceuticals; [General Type] R&D institutions (regenerative medicine institutions) intending to conduct advanced regenerative medicine clinical research; [Deepening Type] R&D institutions (regenerative medicine institutions) intending to verify reproducibility of prior advanced regenerative medicine clinical research.
How do I apply?
Applications follow the official program notice, which is in Korean. See the source link for the method and receiving office; Beaconoi can prepare an English draft for your review.
Which organization runs this program?
This program is administered by Korea Institute of Science and Technology Planning and Evaluation (KISTEP).
Last updated · Source: Korea Institute of Science and Technology Planning and Evaluation (KISTEP) — official notice
※ Program information is compiled from each institution’s public sources; actual eligibility, amounts and deadlines may change. Always verify against the official notice (in Korean) before applying.